PlumeSTARS is proud to announce that it has been selected among the 8 companies that will be able to access the “Business Match in Silicon Valley” and the related preparation and mentoring activities.
Since 2015, the Emilia-Romagna Region has been present in Silicon Valley through the AR-TER Consortium Company, which manages regional internationalization projects towards the Silicon Valley and the permanent facility in San Francisco. Since 2017, the Emilia-Romagna Region has expanded its activities to involve only the startups, but the whole regional innovative ecosystem, starting from the most innovative companies.
The program includes various
operational phases: scientific training – to be carried out both in Emilia
Romagna and in Silicon Valley – up to moments of pitching, investor events and
B2B meetings with possible partners.
The mission in Silicon Valley will be held from 18 to 22 November 2019 and foresees the realization of meetings personalized and group meetings between a representative of up to 8 companies selected and potential partners interested in Silicon Valley.
PlumeStars and Biopharmanet-Tec will attend together with the company Lisapharma spa The Eight World Congress of Orphan Medicines, in Barcelona on 14 and 15 November 2017.
The Congress brings together companies, start-ups and stakeholders in the field of orphan diseases and rare diseases.
Read more “14-15 November: the Eight World Congress of Orphan Medicinal Products in Barcelona”
Cardiovascular diseases, such as myocardial infarct and heart failure, represent a societal burden, accounting for more than 30% of deaths globally and spending yearly ~190 billion € in European healthcare. The chronic treatment of patients leads only to short-term benefits, since the conventional therapies show several weak points.
Read more “The nano-revolution reaches the heart: the EU-funded project CUPIDO”
On 28 February 2021, the World Day of Rare Diseases was celebrated, a very significant celebration, which, since 2008, has contributed to keep the attention on rare diseases high and to “turn on the light” on them, as per the slogan chosen by UNIAMO (Federation of Associations of People with Rare Diseases of Italy).
Read more “PlumeStars published a new scientific paper”
PlumeStars is pleased to annonuce that has been selected for participating at the important X-HUB TOKYO’S INBOUND PROGRAM 2021.
X-HUB TOKYO’S INBOUND PROGRAM, sponsored by the Tokyo Metropolitan Government, is an accelerator program that provides opportunities for global startups in the field of FinTech, Mobility, and Life Science to enter Tokyo market.
Read more “PlumeStars has been selected with other 41 global startups for X-HUB TOKYO’S INBOUND PROGRAM”
Prof. Paolo Colombo, CEO of PlumeStars srl, has been invited to enter in the rExpert committee of the research project called AEROPERF. The project will take place in Liège, Belgium, subsidized by the Wallon Region. The Expert Committee included Prof. Nicolas Tsapis of Paris-Sud University and Marco Laackmann of Haro Hofliger.
Read more “Prof. Paolo Colombo invited in the Expert Committee of AEROPERF research project”
We are pleased to announce that PlumeStars has received the certification “Seal of Excellence” delivered by the European Commission, as the institution managing Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020.
Read more “Hyalcis’s SEAL OF EXCELLENCE certificate by the European Commission”
We are pleased to announce that the Controlled Release Society (CRS) has announced the election of Paolo Colombo, Pharm. D., Ph.D., CEO of PlumeStars, Emeritus Professor, Department of Food and Drug, University of Parma, Italy to its College of Fellows.
Read more “PAOLO COLOMBO ELECTED INTO CONTROLLED RELEASE SOCIETY (CRS) COLLEGE OF FELLOWS”